The Filgrastim Market report is equipped with market data from 2013 to 2023. The report gives a market overview covering key drivers and risks factors. The report is bifurcated by top global manufactures mentioning sales, revenue and prices as applicable. It also evaluates the competitive scenario of the leading players. The report expands to cover regional market data along with type and application. The report forecasts sales and revenue from 2018 to 2023. The detailed sales channel is also covered in the study.
Filgrastim is a granulocyte colony-stimulating factor in humans and a hematopoietic agent utilized for prevention of infection and neutropenic (low count of WBCs) fevers triggered by chemotherapy, HIV/AIDS, radiation poisoning, or others. Filgrastim can be administered by subcutaneous injection or infused into vein by IV.
Scope of the Report:
This report focuses on the Filgrastim in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Filgrastim is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017.
Market Segment by Manufacturers, this report covers
- Cadila Pharmaceuticals
- Abbott
- Dr. Reddy's
- Intas Biopharmaceuticals
- Amgen
- Emcure Pharmaceuticals
- Reliance Life Sciences
- Sandoz(Novartis)
- Biocon
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- In-House Manufacturing
- Contract Manufacturing Organizations
Market Segment by Applications, can be divided into
- Oncology
- Chronic and Autoimmune Diseases
- Blood Disorders
- Growth Hormone Deficiency
- Infectious Diseases
- Other Applications
There are 15 Chapters to deeply display the global Filgrastim market.
Chapter 1, to describe Filgrastim Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Filgrastim, with sales, revenue, and price of Filgrastim, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Filgrastim, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Filgrastim market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Filgrastim sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source